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Poster Session I S231approach have been identified. Recently CD40-activated B cells
(CD40-B) have been studied as complementary antigen presenting
cells. They can be expanded from small amounts of PB at.95% pu-
rity underGMP-like conditions and efficiently prime and expand na-
ı¨ve T cells in vitro. Importantly these cells are available at virtually
unlimited amounts for high-dose, high-frequency vaccination con-
sidered crucial for the control of cancer in vivo.
Methods and Results: For preclinical in vivo testing using high-
dose, repetitive vaccinations with CD40-B we developed a murine
system to study their ability to induce immune responses in vivo.
mCD40B are generated from murine splenocytes by co-culture
with murine CD40-Ligand and addition of IL-4. mCD40B cells
could be expanded more than 6-fold within 14 days and .90% pu-
rity. mCD40B were used to establish a vaccination model to study
induction of tumor- and auto-antigen specific immune responses
as well as toxicity of very-high-dose injections (VHD) in B6 mice.
To determine long-term toxicity mice were vaccinated twice weekly
for 5 weeks using high-doses (310^6  110^8/kg) of mCD40B.
This is about 2-3 log higher than currently used in DC vaccinations
in humans. Acute toxicity was assessed by vaccinatingmice once with
VHD (110^7 3.310^8/kg). There was no difference in survival,
weight and clinical appearance compared to control mice. Histo-
pathological assessment did not reveal any pathologic changes. Mu-
rine Mixed Lymphocyte Reaction was established to investigate the
immune-stimulatory capacity of mCD40B in comparison to mDC
through detection of T cell proliferation in vitro. Immune monitor-
ing by intracellular cytokine staining for IFN-g and assessment of in
vivo cytotoxicity revealed that mCD40B vaccination leads to in-
creased IFN-g production by activated T cells and specific lysis of
CFSE-labelled peptide-pulsed target cells.
Conclusion:Based on these findings thatmCD40B induceT cell re-
sponses in vitro and in vivo we are now developing the optimal
mCD40B vaccination algorithm for preventive and therapeutic
treatment of B16-Melanoma in B6 mice as a next step towards future




(n5 30) MRD (n5 10) CB (n5 20) p value
-year OS
(95%CI)
47% (28%-66%) 50% (19%-80%) 44% (20%-68%) 0.9
-year PFS
(95%CI)
39% (21%57%) 40% (10%-70%) 39% (27%-60%) 0.8
-month TRM
(95%CI)
13% (1%-26%) 20% (0-43%) 10% (0-23%) 0.6197
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT)
USING FLUDARABINE/TREOSULFAN CONDITIONING REGIMEN COM-
PARED WITH BUSULFAN-BASED MYELOABLATIVE AND REDUCED-IN-
TENSITY CONDITIONING IN PATIENTS WITH AML AND MDS; RELATIVE
OUTCOMES DEPEND ON DISEASE STATUS AT SCT
Shimoni, A., Shem-Tov, N., Rand, A., Volchek, Y., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Allogeneic SCT with both myeloablative (MAC) and reduced-in-
tensity conditioning (RIC) is effective therapy in AML/MDS. How-
ever, the relative merits of each differ in different settings.
Fludarabine/treosulfan (FT) has been reported as an effective regi-
men in AML/MDS with limited toxicity. However, the relative
dose intensity and expected outcomes with FT in the different
SCT settings, compared with Busulfan (Bu)-based regimens, is not
well defined. We analyzed the outcomes of 298 pts with AML/
MDS given SCT from sibling (n5 153) or unrelated (n5 145) do-
nors. Pts meeting standard eligibility criteria forMACwere given iv-
BuCy (n5 81). Pts at high risk for MAC were given fludarabine and
reduced doses of ivBu (6.4 mg/kg, FB2, n5 91), high dose Bu (FB4,
12.8 mg/kg, n5 63) or treosulfan (30-36 gr/m2, n5 63). Non-re-
lapse mortality was 17%,18%,18% and 20% with FB2,FB4,FT
and BuCy, respectively (p5NS). With a median follow-up of 38
months (1-115), estimated 5-yr overall survival (OS) was
36%,33%,43% and 41%, respectively (p5NS). Multivariate analy-
sis (MVA) defined age. 50 [HR 1.5 (1-2.2), p5 0.05)], active dis-
ease at SCT [HR 2.3 (1.6-3.2), p\0.001)] and unrelated donor
[HR 1.5 (1-2.0), p5 0.02)] as risk factors for shorter OS. The condi-
tioning regimen was not predictive.When the analysis was limited to
pts in remission (n5 126), OSwas 51%,43%,58%, and 43%, respec-
tively. MVA identified age. 50 as an adverse factor, while SCT us-
ing FB2 or FT was associated with longer OS [HR 0.3 (0.2-0.7),
p5 0.002)]. When the analysis was limited to pts with active disease
(n5 172), either chemo-refractory (n5 93) or untreated (n5 79),OS was 12%,25%,32%, and 36%, respectively. MVA identified
chemo-refractory disease as the major adverse factor for OS [HR
2.2 (1.5-3.3), p5 0.001)], while SCT using BuCy or FT was associ-
ated with longer OS [HR 0.7 (0.5-1.0), p5 0.06)]. In conclusion,
dose intensity is associated with different outcomes in the different
settings. In pts in remission, outcome is mostly related to SCT tox-
icity resulting in an advantage to less intensive regimens, such as
FB2, while FT shares this characteristic. In pts with active disease,
outcome is dominated by the risk for relapse, leading to advantage
of more intensive regimens, such as BuCy. FT shares this character-
istic mainly in pts with no true chemo-refractoriness and has an ad-
vantage over FB2 in this setting. FT should be considered a reduced
toxicity myeloablative conditioning that is feasible in pts ineligible
for MAC.198
SIMILAR AND PROMISING OUTCOMES IN OLDER AML PATIENTS IN FIRST
COMPLETE REMISSION AFTER REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD AND SIBLING DONOR TRANSPLANTATION
Oran, B., Quing, C., Brunstein, C., Majhail, N., Weisdorf, D. University
of Minnesota, Minneapolis, MN
Background: AML has a worse prognosis in older patients indepen-
dent of karyotype abnormalites at the time of diagnosis. However
this group has not been adequately represented in major trials eval-
uating the role of allogeneic allogeneic hematopoietic stem cell
transplantation (HSCT) in AML. Here we present our results with
allogeneic HSCT in older AML patients in first complete remission
(CR1).
Methods:We retrospectively analyzed 30 consecutive patients$ 55
years who underwent their first HSCTwith a matched related donor
(MRD) or cord blood (CB) at the University of Minnesota for AML
in CR1 between January 1995 and December 2007. Study outcomes
were overall survival (OS), progression free survival (PFS) and trans-
plant related mortality (TRM).
Results: Median age was 60 (range 55-68) years; 8 had evolved
from MDS. Thirteen (43%) patients had intermediate risk (all
with normal karyotype) and 17 (57%) had poor risk karyotype.
Donors were MRD (n5 10) and CB (n5 20). Median time
from diagnosis to HSCT was 4.5 months (range 2.6-14.4). Re-
duced intensity conditioning was used in all cases and 27 of 30
(90%) received total-body irradiation (200 cGy), cyclophospha-
mide and fludarabine. Graft versus host disease (GVHD) prophy-
laxis was cyclosporine and mycophenolate mofetil in 27 of 30
patients (90%).
The median follow-up of survivors was 35.3 months (range 9.4-
62.4 months). The probability of 3-year OS was 50% (95% confi-
dence interval (CI), 19%-80%) for MRD and 44% (95% CI, 20%-
68%) for CB (p5 0.9) (Table 1). The probability of 3-year PFS
was 40% (95%CI, 10%-70%) for MRD and 39% (95% CI, 27%-
60%) for CB (p5 0.8). On univariate analysis, poor risk karyotype
and time to transplantation from diagnosis had no impact on disease
outcomes. Grade II-IV aGVHDwas observed in 9 patients (4 MRD
and 5 CB). Chronic GVHD was documented in 10 patients (33%).
Thirteen patients are alive at last contact. Eight of 13 were in remis-
sion and free of all immunosuppression at a median of 24 months
(range 6-32 months). The primary causes of death were relapse
(MRD5 1, CB5 7), infection (MRD5 1, CB5 3), acute GVHD




S232 Poster Session I0%-43%) and 10% (95%CI, 0%-23%) for MRD and CB, respec-
tively (p5 0.6)
Conclusion:The use of allogeneic HSCTwith RIC provides favor-
able disease outcomes in older AML patients in CR1. CB should be
considered as an alternative donor source in patients with no MRD
donor available.199
SYNERGISTIC CYTOTOXICITY OF CLOFARABINE, FLUDARABINE AND BU-
SULFAN: RELEVANCE TO MYELOABLATIVE THERAPY
Valdez, B.C.1, Li, Y.1, Murray, D.2, Champlin, R.E.1, Andersson, B.S.1
1UT M.D. Anderson Cancer Center, Houston, TX; 2Cross Cancer Insti-
tute, Edmonton, AB, Canada
Clofarabine (Clo) and Fludarabine (Flu) are purine nucleoside an-
alogues (NA) with antileukemia activity. Their synergistic cytotoxic-
ity in the absence or presence of DNA alkylating drug Busulfan (Bu)
has not been reported. To determine the efficacy and synergism of
these three drugs in Bu-resistant AML cell line (KBM3/Bu2506),
various combinations were analyzed for their cytotoxicity. Clo, Flu
and Bu have IC50 values of 0.03 mM, 1.22 mM and 126 mM, respec-
tively. Combination of 0.01 mM Clo and 0.2 mM Flu resulted in
84% cell survival after 4 d; addition of 40 mMBu to this combination
decreased cell survival to 59% suggesting synergism. Cell cycle anal-
ysis after 2-day exposure of cells to either 0.015 mM Clo or 0.6 mM
Flu showed 6% cells in sub-G1. When combined at the same con-
centrations, 20% cells were in sub-G1 and 5% were TUNEL-posi-
tive. Addition of 80 mM Bu to this combination increased sub-G1
and TUNEL-positive cells to 35% and 15%, respectively. These re-
sults suggest synergistic efficacy of Clo and Flu which further im-
proves with addition of Bu. Immunoblot analysis of cells exposed
to 0.015 mM Clo + 0.6 mM Flu resulted in significant cleavage of
PARP1 and increased g-H2AX compared with exposure to either
NA alone; addition of 80 mM Bu increased the effects two-fold.
These results suggest drug-mediated induction of DNA damage re-
sponse and apoptosis. Inhibition of ribonucleotide reductase (RNR)
with 100 mMhydroxyurea (HU) was also synergistic with Clo or Flu.
The effects of [Clo + Flu], [Clo +HU] and [Flu +HU] were reversed
by 100 mM cytidine. These data support self-potentiation of [Clo + -
Flu] combination as a possible mechanism of their synergistic cyto-
toxicity where both NA inhibit RNR, decrease deoxynucleotide
synthesis and make more deoxycytidine kinase available to phos-
phorylate and activate Clo and Flu. This mechanism may result in
enhanced incorporation of Clo and Flu during DNA synthesis.
[Clo + Flu] combination also resulted in more significant methyla-
tion of histone H3 suggesting increased chromatin remodeling
which possibly exposed more DNA to Bu-mediated cross-linking
and explains the observed synergism of [Clo + Flu + Bu]. This model
is consistent with a dramatic increase in the level of g-H2AX, an in-
dicator of DNA damage, when Bu was added to [Clo + Flu] combi-
nation. Overall, our results suggest that addition of [Clo + Flu]
might synergistically improve the cytoreductive efficacy of Bu-based
pre-transplant regimen in myeloid leukemia patients.200
EFFECTS OF CHANGES IN CONDITIONING REGIMEN AND SUPPORTIVE
CARE ON OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Abello, V., Rosales, C., Pedraza, E., Linares, A., Esguerra,H., Rosales,M.,
Figueroa, J. Clınica de Marly, Bogota, Colombia
As in all centers around de world, transplant strategies have change
in our center over the time.Here we report the results of a single cen-
ter, retrospective analysis of outcomes in patients with AML treated
with high dose therapy and allo-SCT, from 1994 to 2009, comparing
patients treated before and after 2005whenwe changed conditioning
regimen for AML to Fludarabine-Busulfan and implemented sup-
portive measures as Levofloxacine as prophylaxis, CMV pre-emptive
strategy, and EICH prophylaxis with Micofenolate (MMF).
Since 1994, 59 LMA patients have been treated, 57 received pe-
ripheral blood HLA identical related grafts and 2 patients receivedUR cord blood transplants. As conditioning, 3 patients received
RIC and 56 full intensity conditioning (BuCy 25 – BuFlu 23 – other
8). Only 3 (5%) had high risk cytogenetics at diagnosis but 40%were
considered of high risk at transplantation (44% for BuCy and 39%
for BuFlu). Table 1. Describes patient characteristics and outcomes
for all patients and BuCy vs BuFlu groups. Of note BuCy and BuFlu
groups are very similar except for CMV positivity 56 vs 78% and
time from diagnosis to transplant 24 months (2.3-167) vs 14.5
(2.13-33).
BuFlu patients received routine Levofloxacine prophylaxis (78%
vs 0% BuCy group), GVHD mainly with Cs-MMF (69% vs BuCy
group 28%) and were treated for CMV in a preemptive strategy.
As shown in table toxicity related to the procedure was greatly re-
duced with BuFlu strategy, having a shorter hospital stay, less fever,
diarrhea, requiring less antibiotics and transfusion support. There
were no toxic deads in BuFlu group.
For BuCy group, at a median follow-up of 12.8 months (range 0.5-
118.), 9 patients are alive in CR (36%), 4 were lost for follow-up
(16%) and 12 died (48%). 4 patients (16%) died before day 100 of
transplant related causes. Main cause of death was relapse in 7
(58.3%).
For BuFlu group, at a median follow-up of 7 months (range 1-40),
13 (56.5%) are alive in CR, 1 is alive in relapse (4.3%) and 9 died
(39.1%). No patient died before day 100. Relapse has been the
main cause of dead so far, 4 (33.3%); followed by pulmonary compli-
cations, 3 (25%) and EICH related complications 2 (16.7%).
This retrospective analysis suggest benefit of Bu-Flu and newer
supportive strategies in early toxicity related to HLA familial allo-
SCT over BuCy. Longer follow-up and greater numbers of patients
are needed to draw conclusions about its significance in long-term
survival.
Patient characteristics and outcomes
All (N 59) BuCy (N. 25) Bu-Flu (N. 23)Gender (M/F) 32/27 12/13 14/11
Age 34 (6-63) 34.9 (6-55) 33.8 (10-61)
# Previus cycles 4.67 (1-16) 4.5 (1-16) 4.7 (1-9)
CD341x10-6/kg 3.3 (0.3-11.1) 2.9 (1.1-8) 2.9 (0.8-11)
Hospital stay 32.1 (21-80) 34.7 (22-54) 27.3 (22-40)
% weigth loss 5 (-3.4 – 13.6) 6 (0-12.9) 3.7 (-3.4-12.1)
Neutrophyls graft 13 (6-43) 14 (9-43) 11 (6-14)
Fever (days) 4.1 (0-22) 4.8 (1-20) 1.9 (0-5)
Diarrhea (days) 3.9 (0-21) 5 (0-15) 2.9 (0-21)
TPN (days-% patients) 6.2 (0-25)-61% 8.3 (0-21)-72% 3.1 (0-10)-48%
Antibiotic days 32.4 (0-127) 42.56 (12-127) 17 (0-49)
RBC transfusion 1.8 (0-28) 1.92 (0-14) 0.6 (0-5)
PLT transfusion 4.9 (0-35) 6.5 (1-27) 1.4 (0-18)
Mortality\100 days 6.7% 16% 0%201
UNRELATED DONOR REDUCED-INTENSITY STEM CELL TRANSPLANTA-
TION IS A PROMISING TREATMENT OPTION FOR ELDERLY PATIENTS
WITH BLASTIC PLASMOCYTOID DENDRITIC CELL NEOPLASM (BPDC)
Dietrich, S.1, Hegenbart, U.1, Schmitt, T.1, Martens, U.2, Ho, A.D.1,
Dreger, P.1 1University of Heidelberg, Heidelberg, Germany; 2SLK-Kli-
niken, Heilbronn, Germany
Blastic plasmacytoid dendritic cell neoplasm (BPDC), formerly
known as blastic NK cell lymphoma, is a rare hematopoietic malignancy
preferentially involving skin, bone marrow and lymph nodes. The
overall prognosis of BPDC is dismal. Most patients show an initial
response to acute leukemia-like chemotherapy, but relapses with
subsequent drug resistance occur in virtually all patients resulting
in a median overall survival of only 9-13 months. However, anec-
dotal long-term remissions have been reported in young patients
who received early myeloablative allogeneic stem cell transplanta-
tion (alloSCT). As the median age at diagnosis is above 60 years,
most patients at risk will not be eligible for myeloablative alloSCT.
Here we present our experience with reduced-intensity conditioning
(RIC) alloSCT from unrelated donors in elderly patients with
BPDC.
